Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoer Jinqiao granules (also known as Xiaoer Qingiao granules) is a traditional Chinese patent medicine developed and manufactured by Sichuan Kaijing Pharmaceutical, a subsidiary of Yifan Pharmaceutical. It is formulated from seven traditional Chinese herbs: Lonicera japonica (honeysuckle), Forsythia suspensa, Pueraria lobata (kudzu root), Isatis tinctoria (isatis leaf), Sophora tonkinensis (tonkin sophora root), Bupleurum chinense (bupleurum root), and Glycyrrhiza uralensis (licorice). The granules are primarily indicated for the treatment of wind-heat syndrome in children, which manifests as fever, aversion to cold, sore throat, difficulty swallowing, and cough. It is widely used in China for pediatric acute tonsillitis and is being evaluated in Phase 4 clinical trials for pediatric influenza.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaoer Jinqiao granules.